Homeopathy

Source: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=homeopathy(=eng

Extracted: 2025-08-26T06:37:34.863572

Homeopathy (PDF Version - 398 KB) This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredients. Notes By submitting a PLA referencing this monograph, the applicant is attesting that the product will comply fully with the recommended conditions of use outlined in this monograph. The conditions of use include methods of preparations, source materials, doses, durations of use, combinations of medicinal ingredients, and risk statements. Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant's discretion. The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant. Date August 5, 2019 Proper name(s), Common name(s), Source material(s) Notes The proper name(s), common name(s) and source material(s) must be as per the homeopathic monograph referenced as the Standard or Grade (please refer to the specifications). The medicinal ingredient(s) must be a permitted substance with a homeopathic monograph in one of the Natural and Non-Prescription Health Products Directorate (NNHPD) accepted homeopathic pharmacopoeias 1,2,3,4,5. Medicinal ingredients considered imponderables are not included within the scope of this monograph. Route(s) of administration The acceptable route(s) of administration must be acceptable as per the NNHPD Evidence for Homeopathic Medicines guidance document. Dosage Form(s) The acceptable pharmaceutical dosage forms include, but are not limited to those indicated in Table 1 below. This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document. Use(s) or Purpose(s) Homeopathic preparation/remedy/medicine. Dose(s) Subpopulation(s) As specified below. Quantity(ies) Table 1. Dosage forms and their recommended dose for each subpopulation Dosage Form(s) Subpopulation(s) General dosing Maximum Acute Dosing (Optional) Maximum Dosing Maximum Frequency Globules (small pellets, pills) (Oral) Adolescents 12-17 years and Adults 18 years and older 1 whole unit dose(tube or container) 1 time per day 10-20 granules, 2-3 times per day Children 1-11 years* Infants 0-11 months* Granules (regular or large pellets) Adolescents 12-17 years and Adults 18 years and older 3-5 granules 2-3 times per day Every 15-60 minutes (not to exceed 12 times per day) or until improvement of symptoms. Then resume general dosing. Children 1-11 years* Infants 0-11 months* Tablets Adolescents 12-17 years and Adults 18 years and older 1-4 tablets 1-4 times per day Every 15-60 minutes (not to exceed 12 times per day) or until improvement of symptoms. Then resume general dosing. Children 6-11 years 1-3 tablets 1-4 times per day Children 1-5 years* 1/2-3 tablets 1-3 times per day Infants 0-11 months* 1/2-3 tablets 1-2 times per day Oral Drops Adolescents 12-17 years and Adults 18 years and older 10-30 drops 1-3 times per day Every 15-60 minutes (not to exceed 12 times per day) or until improvement of symptoms. Then resume general dosing. Children 6-11 years 5-15 drops Children 1-5 years 5-10 drops Infants 0-11 months 1-5 drops Liquid(Oral drinkable vials) Adolescents 12-17 years and Adults 18 years and older 1 ampoule 1-3 times per day Not to exceed 3 times per day Children 6-11 years 2/3 ampoule Children 1-5 years ½ ampoule Infants 0-11 months 1/3 ampoule Oral solution (Unit dose) Adolescents 12-17 years and Adults 18 years and older Unit oral dose 1-3 times per day Give one unit dose upon onset of symptoms. Repeat two more times at 15-minute intervals. Repeat process up to 9 times per day if symptoms reappear. Children 1-11 years Infants 0-11 months Oral Syrup Adolescents 12-17 years and Adults 18 years and older 1-2 tsp Every 4 to 6 hours N/A Children 1-11 years ½-1 tsp 1-3 times per day Infants 0-11 months ½ tsp 1-3 times per day Cream or Ointment Infants 0-11 months, Children 1-11 years, Adolescents 12-17 and Adults 18 years and older Cover affected area Use as needed N/A Nasal spray Adolescents 12-17 years and Adults 18 years and older 1-2 sprays/ nostril 3-5 times per day N/A Children 1-11 years 1 spray/nostril 4 times per day Infants 0-11 months 1 spray/nostril 4 times per day Eye Drops Adolescents 12-17 years and Adults 18 years and older 2-3 drops 3 times per day 1 drop in the affected eye every 15 minutes for a maximum of 3 hours. Children 1-11 years 1-2 drops 3 times per day Infants 0-11 months 1 drop 2 times per day Ear Drops Adolescents 12-17 years and Adults 18 years and older 1 complete vial 3 times per day Every 15-60 minutes (not to exceed 12 times per day) or until improvement of symptoms. Then resume general dosage. Children 1-11 years 3-4 drops Infants 0-11 months 2-3 drops Suppositories Adolescents 12-17 years and Adults 18 years and older 1 suppository 1-4 times per day Maximum 5 times per

day Children 6-11 years 1-3 times per day Maximum 4 times per day Children 1-5 years 1-2 times per day Maximum 3 times per day Infants 0-11 months 1-2 times per day Maximum 2 times per day *Dissolve dose in a small amount of water before administration to infants and children 0-5 years old. Potency The homeopathic potency of each medicinal ingredient must be at or above the minimum potency specified in the Natural Health Products Ingredients Database (NHPID). Note The minimum potencies indicated in the NHPID are generally based on the following unless specific safety concerns have been identified: The OTC limit for HPUS 4D for HAB 12 CH for pharmacopoeia other than HPUS or HAB/GHP Method(s) of preparation The method(s) of preparation must be as per the homeopathic monograph referenced as the Standard or Grade (please refer to the specifications). It is also acceptable to use another method from an NNHPD accepted homeopathic pharmacopoeia not referenced as the Standard or Grade. In this case, the selected method of preparation must be appropriate for the medicinal ingredient. Direction(s) for use Use as directed by a health care practitioner/health care provider/health care professional/doctor/physician. Duration(s) of Use No statement required. Risk Information Caution(s) and warning(s) Consult a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. Ingredient specific risk statements when required by NHPID. Contraindication(s) No statement required. Known adverse reaction(s) No statement required. Non-medicinal ingredients Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database. Storage conditions No statement required. Specifications The finished product must comply with the requirements outlined in the current NNHPD Evidence for Homeopathic Medicines guidance document. The finished product specifications must be established in accordance with the requirements described in the Natural and Non-prescription Health Products Directorate (NNHPD) Quality of Natural Health Products Guide. The medicinal ingredient(s) must comply with the requirements outlined in the NHPID. All medicinal ingredients of animal origin must be sterilized as per HPUS and HAB requirements or equivalent. If the method of preparation includes the use of natural lactose for trituration, an Animal Tissue form for lactose must be submitted. Standard or Grade Must reference a homeopathic monograph in one of the most recent versions of NNHPD accepted homeopathic pharmacopoeias: HPUS 1, HAB/GHP 2, PhF 3, Ph.Eur. 4, EHP 5.1 Homeopathic Pharmacopeia of the United States (HPUS) 2 Homoopathisches ArzneiBuch (HAB) or German Homeopathic Pharmacopoeia (GHP) 3 Pharmacopée française or French Pharmacopoeia (PhF) 4 European Pharmacopoeia (Ph.Eur.) 5 Encyclopedia of Homeopathic Pharmacopoeia (EHP) References Cited EHP 2002: Encyclopaedia of Homeopathic Pharmacopoeia, Volume 3. New Delhi (IN): Kuldeep Jain and B.Jain, 2002. GHP 2008: German Homeopathic Pharmacopoeia, Volume 1.Stuttgart (DE): MedPharm, 2008. HAB 2003: Homöopathisches ArzneiBuch, Band 1. Stuttgart (DE): MedPharm, 2003. HPUS 2004: Homeopathic Pharmacopeia of the United States, Revision Service. Pennsylvania (PA): Homeopathic Pharmacopoeia Convention of the United States, 2004. Ph.Eur. 2011: European Pharmacopoeia, 7th edition. Strasbourg (FR): Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM), 2011. PhF 2003: French Pharmacopoeia, 10th edition. Saint-Denis Cedex(FR): French Agency for the Safety of Health Products , 2003. Report a problem on this page Date modified: 2019-03-01

MEDICINAL INGREDIENT(S)

Notes By submitting a PLA referencing this monograph, the applicant is attesting that the product will comply fully with the recommended conditions of use outlined in this monograph. The conditions of use include methods of preparations, source materials, doses, durations of use, combinations of medicinal ingredients, and risk statements. Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant's discretion. The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant. DateAugust 5, 2019

DOSAGE FORM(S)

This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document.

DOSE(S)

Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant's discretion. The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant.

RISK INFORMATION

Caution(s) and warning(s) Consult a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. Ingredient specific risk statements when required by NHPID. Contraindication(s) No statement required. Known adverse reaction(s) No statement required.

NON-MEDICINAL INGREDIENTS

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database.

STORAGE CONDITION(S)

No statement required.

REFERENCES

EHP 2002: Encyclopaedia of Homeopathic Pharmacopoeia, Volume 3. New Delhi (IN): Kuldeep Jain and B.Jain, 2002.GHP 2008: German Homeopathic Pharmacopoeia, Volume 1.Stuttgart (DE): MedPharm, 2008. HAB 2003: Homöopathisches ArzneiBuch, Band 1. Stuttgart (DE): MedPharm, 2003.HPUS 2004: Homeopathic Pharmacopeia of the United States, Revision Service. Pennsylvania (PA): Homeopathic Pharmacopoeia Convention of the United States, 2004.Ph.Eur. 2011: European Pharmacopoeia, 7th edition. Strasbourg (FR): Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM), 2011.PhF 2003: French Pharmacopoeia, 10th edition. Saint-Denis Cedex(FR): French Agency for the Safety of Health Products, 2003.

Subpopulation(s)	General dosing	Maximum Acute Dosing (Optional)	
Maximum Frequency			
Adolescents 12-17 years and Adults 18 yea	rs1awdodedenit dose(tube or container)	1 time per day	10-20 g

Adolescents 12-17 years and Adults 18 year	rs3afidjralderles	2-3 times per day	Every 1
Adolescents 12-17 years and Adults 18 year	rs1a4dabilbes	1-4 times per day	Every 1
1-3 tablets	1-4 times per day		
½-3 tablets	1-3 times per day		
½-3 tablets	1-2 times per day		
Adolescents 12-17 years and Adults 18 year	rs1analOutteps	1-3 times per day	Every 1
5-15 drops			
5-10 drops			
1-5 drops			
Adolescents 12-17 years and Adults 18 year	rs1aand poolee	1-3 times per day	Not to e
2/3 ampoule			
½ ampoule			
1/3 ampoule			
Adolescents 12-17 years and Adults 18 year	rsLamidontaledose	1-3 times per day	Give on
Adolescents 12-17 years and Adults 18 years	rs1a2idspider	Every 4 to 6 hours	N/A
½-1 tsp	1-3 times per day		
½ tsp	1-3 times per day		
Infants 0-11 months, Children 1-11 years, A	d @eseeratis et :2ett7aaea l Adults 18 years and old	debse as needed	N/A
Adolescents 12-17 years and Adults 18 year	rs1a2idspoteless/ nostril	3-5 times per day	N/A
1 spray/nostril	4 times per day		
1 spray/nostril	4 times per day		
Adolescents 12-17 years and Adults 18 years	rs2a8dd odpe r	3 times per day	1 drop
1-2 drops	3 times per day		
1 drop	2 times per day		
Adolescents 12-17 years and Adults 18 years	rs1a cohophietie vial	3 times per day	Every 1
3-4 drops			
2-3 drops			
Adolescents 12-17 years and Adults 18 year	rs1a su¢pploksit ory	1-4 times per day	Maxim
1-3 times per day	Maximum 4 times per day		
1-2 times per day	Maximum 3 times per day		
1-2 times per day	Maximum 2 times per day		
	,	,	